1. ALTS Group. Human papillomavirus testing for triage of women with cytologic evidence of low – grade squamous intraepithelial lesions: baseline data from a randomized trial. J National Cancer Institute, 2000, 92(5), p. 397–402.
2. Arbyn, M., Autier, R., Ferlay, J. Burden of cervical cancer in the 27 member states of the European Union, Estimates for 2004. Ann Oncol, 2007, 18, p. 1425–1427.
3. Ball, C., Madden, JE. Update on cervical cancer screening: Current diagnostic and evidence-based management protocols. Postgrad Med 2003, 113, 2.
4. Castle, PE. Basic science: beyond human papillomavirus: the cervix, exogenous secondary factors, and the development of cervical precancer and cancer. J Lower Genital Tract Dis, 2004, 8, 3, p. 224–230.
5. Coleman, DV. Internal quality control for cervical cytopathology laboratories. Cytopathology, 1996, 7, p. 1–3.
6. Coleman, D., Day, N., Douglas, G., et al. Committee on Quality Assurance Training and Education of the European Federation of Cytology Societies: European guidelines for quality assurance in cervical cancer screening, Europ. J. Cancer, 1993, 29/A, Suppl. 4, p. 1–30.
7. DeMay, RM. The art and science of cytopathology I: Exfoliative cytology. Chicago: ASCP Press, 1996, p. 462.
8. European guidelines for quality assurance in cervical cancer screening. 2nd ed. IARC. European Communities, 2008, p. 291.
9. Koss, LG. The Papanicolaou test for cervical cancer detection: a triumph and a tragedy. JAMA, 1989, 261, p. 737–743.
10. Manos, MM., Kinney, WK., Hurley, LB., et al. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA, 1999, 281(17), p. 1605–1610.
11. Meijer, C., Cox , T. EM4 – Role of HPV testing in cervical cancer screening
12. Nuovo, J., Melnikow, J., Howell, LP. New tests for cervical cancer screening. Am Family Phys, 2001, 1.
13. Olesen, F. A case- control study of cervical cytology before diagnosis of cervical cancer in Denmark. Int J Epidemiol, 1988, 17, p. 501–508.
14. Petry, KU. HPV Screening zur Früherkennung des Zervixkarzinoms. Gynäkologe, 2003, 36, s. 289–296.
15. Quinn, M., Babb, P., Jones, J., Allen, E. Effect of screening on incidence of and mortality from cancer cervix in England: Evaluation based on routinely collected statistics. BMJ, 1999, 318, p. 904.
16. Segnan, N. Cervical cancer screening. Human benefits and human cost in the evaluation of screening Programmes. Eur J Cancer, 1994, 30, p. 873–875.
17. Schenck, U., Planding, W. Quality assurace by continuous recording of the microscope status. Acta Cytol, 1996, 40, p. 73–80.
18. Solomon, D., Nayar, R. The Bethesda System of Reporting Cervical Cytology, definitions, criteria and explanatory notes, 2nd ed. New York: Springer, 2004, p. 191.
19. Solomon, D., Papillo, JL., Davey, DD. Statement on HPV DNA Test Utilization. Acta Cytol, 2009, 53, 3, p. 249–250
20. Syrjanen, S., Shabolova, IP., Petrovichev, N., et al. Human papillomavirus testing and conventional pap smear cytology as optional screening tools of women at different risk for cervical cancer in the countries of the former Soviet Union. J Lower Genital Tract Dis, 2002, 6, 2, p. 97–110.
21. Winer, RL., Kiviat, NB., et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis, 2005, 191, p. 731–738.